title: Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis.
abstract: Eradication of Pseudomonas aeruginosa (PA) is critical in cystic fibrosis (CF) patients.
  
  
  
  To determine eradication success rate of newly acquired PA and to identify characteristics associated with eradication failure.
  
  
  
  In an observational study, data from patients with newly acquired PA infection from 2007 to 2013 were collected. Clinical variables were compared in patients with and without successful eradication for ≥1year.
  
  
  
  Of 183 patients out of 740 (25%) from 7 CF Centers that had newly acquired PA, eradication succeeded in 72%. Patients with the highest risk of failure had multi-resistant PA, fewer sputum cultures taken, were older, and were diagnosed at a later age. The risk of eradication failure increased by 1.3% with each year of delayed CF diagnosis; successful eradication increased by 17% with each additional sputum culture taken.
  
  
  
  Delayed detection of PA infection leading to delayed treatment and growth of multi-resistant organisms is associated with eradication failure.
authors.affiliation: CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Malena
authors.initials: M
authors.lastname: Cohen-Cymberknoh
authors.affiliation: Medical School, Hebrew University, Jerusalem, Israel.
authors.forename: Noa
authors.initials: N
authors.lastname: Gilead
authors.affiliation: CF Center, Hospital Universitari Vall d' Hebron, Barcelona, Spain.
authors.forename: Silvia
authors.initials: S
authors.lastname: Gartner
authors.affiliation: CF Center, Hospital Universitari Vall d' Hebron, Barcelona, Spain.
authors.forename: Sandra
authors.initials: S
authors.lastname: Rovira
authors.affiliation: Graub CF Center, Schneider Children's Medical Center, Petach Tikva and Sackler Faculty of Medicine, Tel-Aviv University,Israel.
authors.forename: Hannah
authors.initials: H
authors.lastname: Blau
authors.affiliation: Graub CF Center, Schneider Children's Medical Center, Petach Tikva and Sackler Faculty of Medicine, Tel-Aviv University,Israel.
authors.forename: Huda
authors.initials: H
authors.lastname: Mussaffi
authors.affiliation: CF Center, Carmel Medical Center, Haifa, Israel.
authors.forename: Joseph
authors.initials: J
authors.lastname: Rivlin
authors.affiliation: CF Center, Carmel Medical Center, Haifa, Israel.
authors.forename: Michal
authors.initials: M
authors.lastname: Gur
authors.affiliation: CF Center, Carmel Medical Center, Haifa, Israel.
authors.forename: Michal
authors.initials: M
authors.lastname: Shteinberg
authors.affiliation: CF Center, Rambam Medical Center, Haifa, Israel.
authors.forename: Lea
authors.initials: L
authors.lastname: Bentur
authors.affiliation: CF Center, Rambam Medical Center, Haifa, Israel.
authors.forename: Galit
authors.initials: G
authors.lastname: Livnat
authors.affiliation: CF Center, Soroka Medical Center, Beer-Sheva, Israel.
authors.forename: Micha
authors.initials: M
authors.lastname: Aviram
authors.affiliation: Pediatric Pulmonary Unit, Shaare-Zedek Medical Center, Jerusalem, Israel.
authors.forename: Elie
authors.initials: E
authors.lastname: Picard
authors.affiliation: Department of Pediatrics, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel.
authors.forename: Ariel
authors.initials: A
authors.lastname: Tenenbaum
authors.affiliation: CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Shoshana
authors.initials: S
authors.lastname: Armoni
authors.affiliation: CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Oded
authors.initials: O
authors.lastname: Breuer
authors.affiliation: CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: David
authors.initials: D
authors.lastname: Shoseyov
authors.affiliation: CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Eitan
authors.initials: E
authors.lastname: Kerem
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000145:classification / Q000627:therapeutic use; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D007223:Infant; D017053:Infection Control / Q000379:methods / Q000706:statistics & numerical data; D007557:Israel / Q000453:epidemiology; D008297:Male; D054539:Medication Therapy Management; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D011552:Pseudomonas Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity
chemical_list: D000900:Anti-Bacterial Agents
keywords: Cystic fibrosis; Eradication failure; Pseudomonas infection